Oxyntomodulin analogue controlled release - Entera Bio/OPKO Health

Alternative Names: GLP-1/glucagon agonist- Entera Bio/OPKO Health; Oral oxyntomodulin - Entera Bio

Latest Information Update: 03 Oct 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Entera Bio; OPKO Health
Class Anorectics; Gastrointestinal hormones; Glucagon-like peptides; Obesity therapies
Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Sep 2024 Pharmacodynamics and pharmacokinetics data from preclinical studies in Malabsorption syndromes and Obesity released by Entera Bio
12 Sep 2023 Entera Bio and OPKO Biologics enter into a research collaboration agreement to develop oxyntomodulin analogues
12 Sep 2023 Preclinical trials in Malabsorption syndromes in Israel, USA (PO), prior to September 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com